Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Sep;1(2):151-4.
doi: 10.1111/j.1752-8062.2008.00020.x.

The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers

David C Ishizawar  1 , Karen M Janosko, Jeffrey J Teuteberg, Linda M Cadaret, Michael A Mathier, Dennis M McNamara
Affiliations

The beta1-adrenergic receptor mediates the pharmacogenetic interaction of the ACE D allele and beta-blockers

David C Ishizawar et al. Clin Transl Sci. 2008 Sep.

Abstract

The role of beta-receptor selectivity for the interaction between the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and beta-blocker therapy was investigated in 479 subjects with left ventricular dysfunction. Subjects were separated into no beta-blocker, beta1 -selective, and nonselective beta-blocker treatment groups. The D allele adversely affected transplant-free survival for subjects not on beta-blockers (p= 0.004). Treatment with selective beta1-blockers eliminated the impact of the D allele (p= 0.51) in a manner similar to nonselective beta1,2-blockers (p= 0.80). Treatment with beta1-blockers was sufficient to eliminate the adverse impact of the ACE D allele, suggesting this pharmacogenetic interaction is mediated through the beta1-receptor.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Event‐free survival by ACE genotype with no β‐blocker therapy, n= 277, p= 0.004. (B) Event‐free survival by ACE genotype with β‐blocker therapy, n= 202, p= 0.97.
Figure 2
Figure 2
(A) Event‐free survival by ACE genotype, β1‐selective β‐blocker only (n= 85), p= 0.51. (B) Event‐free survival by ACE genotype, β1,2 nonselective β‐blocker (n= 117), p= 0.80.
See this image and copyright information in PMC

References

    1. Sigurdsson A, Swedberg K. The role of neurohormonal activation in chronic HF and postmyocardial infarction. Am Heart J. 1996; 132: 229–234. - PubMed
    1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996; 334: 1349–1355. - PubMed
    1. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, El Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PH, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P. Effects of controlled‐release metoprolol on total mortality, hospitalizations, and well‐being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT‐HF). MERIT‐HF study group. JAMA. 2000; 283: 1295–1302. - PubMed
    1. Bristow M. Mechanisms of action of beta‐blocking agents in heart failure. Am J Cardiol. 1997; 80(11A): 26L–40L. - PubMed
    1. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992; 85: 790–804. - PubMed

Publication types

Substances

LinkOut - more resources